. "Epirubicin"@en . . . . . . . . . "An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. [PubChem]"@en . . . . . "Pidorubicinum"@en . . . . . . "* 65 +/- 8 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 60 mg/m2] * 83 +/- 14 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 75 mg/m2] * 65 +/- 13 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 120 mg/m2] * 69 +/- 13 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 150 mg/m2]"@en . "Epiadriamycin"@en . . "100%"@en . . "bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding"@en . "Pidorubicine"@en . . "Marcel van der Rijst, Johan Wilhelm Scheeren, Dick de Vos, \"Process for preparing epirubicin or acid addition salts thereof from daunorubicin.\" U.S. Patent US5874550, issued September, 1996."@en . "Liberal fluid intake to increase urine output and help the excretion of uric acid."@en . . . . . . . . . "* 21 \u00B1 2 L/kg [60 mg/m2 Dose] * 27 \u00B1 11 L/kg [75 mg/m2 Dose] * 23 \u00B1 7 L/kg [120 mg/m2 Dose] * 21 \u00B1 7 L/kg [150 mg/m2 Dose]"@en . . "Epirubicina"@en . . . . "Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion."@en . . . . "For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer."@en . . . . . . . . "77%"@en . . "4'-Epiadriamycin"@en . . . . . . . . . . . "56420-45-2"@en . "Epirubicine"@en . "approved"@en . " "@en . . . . . "Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively"@en . . "Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity."@en . . . . "# Pharmacia. Ellence\u00AE (epirubicin hydrochloride injection) full prescribing information. New York, NY; 2007 Feb. "@en . . . . . "Pidorubicina"@en . "Epirubicinum"@en . . . . . . . . . . "Epirubicin"@en . . "Humans and other mammals"@en . .